VIA
CRSP icon

Virtus Investment Advisers’s CRISPR Therapeutics CRSP Stock Holding History

Virtus Investment Advisers’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.27M Buy
23,351
+8,457
+57% +$446K 0.3% 161
2026
Q1 		$709K Buy
14,894
+2,838
+24% +$150K 0.2% 176
2025
Q4 		$632K Buy
12,056
+1,291
+12% +$77.3K 0.17% 212
2025
Q3 		$698K Hold
10,765
– – 0.2% 169
2025
Q2 		$524K Buy
10,765
+2,860
+36% +$111K 0.18% 179
2025
Q1 		$269K Buy
+7,905
New +$335K 0.07% 249

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
GP
GSK plc London $602M AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Virtus Investment Advisers's CRSP Position: Q2 2026 in Review

Virtus Investment Advisers increased its CRISPR Therapeutics (CRSP) stake by 57% in Q2 2026, buying an estimated $446K and bringing the position to 23,351 shares worth $1.27M. The position accounts for 0.3% of the portfolio, ranked #161.

Virtus Investment Advisers first reported a position in CRSP in Q1 2025 and has held it in 6 quarters since. 524 funds tracked by Wall St. Rank hold CRSP as of Q2 2026.

  • Virtus Investment Advisers held 23,351 shares of CRISPR Therapeutics worth $1.27M as of Q2 2026.
  • Virtus Investment Advisers bought 8,457 CRISPR Therapeutics shares in Q2 2026, an estimated $446K.
  • CRISPR Therapeutics made up 0.3% of Virtus Investment Advisers's portfolio in Q2 2026, its #161 holding.
  • Virtus Investment Advisers first reported a position in CRISPR Therapeutics in Q1 2025 and has held it in 6 quarters since.
  • 524 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q2 2026.

Based on Virtus Investment Advisers's 13F filing for Q2 2026, filed 11 Aug 2026.